ALK-positive non-small cell lung cancer

ASCO: Roche's Alecensa stays on top of Xalkori with long-term survival showing
Fierce Pharma
Wed, 05/13/20 - 10:33 pm
Roche
ASCO 2020
Xalkori
Alecensa
Pfizer
ALK-positive non-small cell lung cancer
Takeda sets sights on first-line lung cancer market with new Alunbrig data
Pharmaforum
Mon, 11/25/19 - 09:49 am
Takeda
Alunbrig
clinical trials
Pfizer
Xalkori
ALK-positive non-small cell lung cancer
Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce Pfizer’s Xalkori
Fierce Pharma
Sat, 11/23/19 - 04:12 pm
Pfizer
Xalkori
ALK-positive non-small cell lung cancer
Takeda
Alunbrig
NICE backs Takeda’s Alunbrig in second-line lung cancer
Pharmaforum
Sat, 02/16/19 - 12:02 am
NICE
Takeda
Alunbrig
ALK-positive non-small cell lung cancer
FDA approves Pfizer's treatment for certain lung cancer patients
Yahoo/Reuters
Sat, 11/3/18 - 12:33 pm
Pfizer
FDA
Lorbrena
ALK-positive non-small cell lung cancer
More Positive Results For Takeda's Alunbrig Acquisition
CP Wire
Wed, 07/25/18 - 09:34 am
Takeda
Alunbrig
ALK-positive non-small cell lung cancer
More Positive Results For Takeda's Alunbrig Acquisition
Wed, 07/25/18 - 08:49 am
Takeda
Alunbrig
ALK-positive non-small cell lung cancer
NICE nods for AbbVie in hep C and Novartis in lung cancer
Pharma Times
Sun, 12/10/17 - 09:53 am
NICE
AbbVie
hepatitis C
Maviret
Novartis
Zykadia
ALK-positive non-small cell lung cancer
Novartis' Zykadia gets 1st-line nod in ALK+ lung cancer
BioPharma Dive
Thu, 06/1/17 - 09:00 am
Novartis
Zykadia
ALK-positive non-small cell lung cancer
Takeda's Ariad deal pays off with blockbuster green light for Alunbrig
Fierce Pharma
Sat, 04/29/17 - 10:04 am
Takeda
Ariad Pharmaceuticals
Alunbrig
ALK-positive non-small cell lung cancer
The FDA opens an inside track to let Novartis race ahead on Zykadia as Roche rivalry heats up
Endpoints
Thu, 02/23/17 - 09:23 am
FDA
Novartis
Zykadia
ALK-positive non-small cell lung cancer
non-small cell lung cancer
Roche
Alecensa